Novavax (NVAX) Cash & Equivalents (2010 - 2025)

Novavax's Cash & Equivalents history runs 16 years deep, the most recent figure standing at $10.9 million for Q4 2025.

• In Q4 2025, Cash & Equivalents rose 2.35% year-over-year to $10.9 million; the TTM figure through Dec 2025 stood at $10.9 million (up 2.35% YoY), while the FY2025 annual figure was $10.9 million, up 2.35% from the prior year.
• Cash & Equivalents was $10.9 million for Q4 2025 at Novavax, down from $268.0 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $2.0 billion in Q1 2021 to a low of $10.3 million in Q2 2022.
• Historically, Cash & Equivalents has averaged $417.1 million across 5 years, with a median of $28.9 million in 2021.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents plunged 99.44% in 2022, then soared 5937.13% in 2023.
• A 5-year view of Cash & Equivalents shows it stood at $1.5 billion in 2021, then slumped by 99.32% to $10.3 million in 2022, then gained by 1.17% to $10.4 million in 2023, then gained by 1.94% to $10.6 million in 2024, then advanced by 2.35% to $10.9 million in 2025.
• The last three Cash & Equivalents figures came in at $10.9 million (Q4 2025), $268.0 million (Q3 2025), and $10.7 million (Q2 2025), per Business Quant data.